MajorAntiretroviral, HIV protease inhibitor×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
CYP3A4 and CYP2J2 metabolise rivaroxaban, as do CYP-independent pathways. In vitro, rivaroxaban is a substrate of the transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 5.2). Atazanavir inhibits CYP3A4, and its effect on P-gp is unknown and cannot be ruled out (atazanavir SmPC, EMA, section 4.5). Ritonavir, which is added to atazanavir to raise its levels, inhibits CYP3A4 more strongly than atazanavir and strongly inhibits P-gp. In the fixed-dose atazanavir/cobicistat tablet, cobicistat inhibits CYP3A4 and/or P-gp. Rivaroxaban levels may therefore rise, and with them the risk of bleeding (atazanavir and atazanavir/cobicistat SmPCs, EMA, sections 4.2 and 4.5). Ritonavir 600 mg twice daily raised the rivaroxaban area under the concentration–time curve (AUC) 2.5-fold and its peak level 1.6-fold, which may increase the bleeding risk. In the atazanavir regimen, ritonavir is taken as 100 mg once daily (rivaroxaban SmPC, EMA, section 4.5; atazanavir SmPC, EMA, section 4.2). There are no pharmacokinetic data on this specific combination (European Heart Rhythm Association, EHRA, 2021 practical guide, Table 9).
Symptoms
The main risk is bleeding. The most frequently reported bleeding events with rivaroxaban were nosebleeds (4.5%) and gastrointestinal bleeding (3.8%). Occult or overt bleeding can occur in any tissue or organ, can lead to anaemia and may be fatal (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.8). In people with haemophilia A and B treated with protease inhibitors, increased bleeding has been reported, including spontaneous skin haematomas and haemarthrosis. A causal link has been proposed, although the mechanism is unknown (atazanavir SmPC, EMA, section 4.4).
Management
The combination is not recommended. The rivaroxaban SmPC advises against rivaroxaban in people on systemic treatment with human immunodeficiency virus (HIV) protease inhibitors and describes them as strong inhibitors of CYP3A4 and P-glycoprotein (P-gp) (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4 and 4.5). Atazanavir is a protease inhibitor (atazanavir SmPC, EMA, section 5.1). The EU atazanavir and atazanavir/cobicistat SmPCs advise against rivaroxaban with the atazanavir plus ritonavir regimen and with the fixed-dose atazanavir/cobicistat tablet (atazanavir and atazanavir/cobicistat SmPCs, EMA, section 4.5). The standard regimen in Europe is atazanavir with ritonavir. Ritonavir may be withdrawn only under restricted conditions, and then the possibility that atazanavir without ritonavir changes rivaroxaban levels is taken into account (atazanavir SmPC, EMA, sections 4.4 and 4.5). The 2021 practical guide of the European Heart Rhythm Association (EHRA) marks rivaroxaban with HIV protease inhibitors in red, which means contraindicated or not advisable because of increased plasma levels. For atazanavir alone, the guide suggests considering avoiding the combination. With ritonavir or cobicistat, it considers direct oral anticoagulants not advisable (EHRA 2021, Tables 5 and 9). The US labels also advise against rivaroxaban with atazanavir plus ritonavir. Rivaroxaban is avoided with drugs that inhibit P-gp and strongly inhibit CYP3A, such as ritonavir (atazanavir and rivaroxaban labels, US Food and Drug Administration, FDA, sections 5.6, 7.2 and 7.3). For atazanavir without ritonavir, the US atazanavir label recommends close monitoring (atazanavir FDA label, section 7.3). If rivaroxaban and atazanavir are nevertheless taken together, watch closely for signs of bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop rivaroxaban if severe bleeding occurs (rivaroxaban SmPC, EMA, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Xarelto (rivaroxabán) – ficha técnica en CIMA (2026)– AEMPS CIMA, Xarelto 20 mg comprimidos recubiertos con película, nº registro 08472018 (EU/1/08/472), secciones 4.3, 4.4 y 4.5
- FDA: Xarelto (rivaroxaban) prescribing information (2026)– FDA label, DailyMed setid 10db92f9-2300-4a80-836b-673e1ae91610, version 65, revised 09/2026, sections 5.2 and 7
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Atazanavir/cobicistat (EU/1/15/1025), sección 4.5 (2026)– EMA, Evotaz 300 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, secciones 4.3 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5